Osman Kibar lays down his hand at Samumed, stepping away from CEO role as his once-heralded anti-aging biotech rebrands
Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. That level of fanfare was nowhere to be found on Thursday, when the company added another $120 million to its coffers and quietly changed its name to Biosplice Therapeutics.
Why the sudden rebrand?
“We did that for obvious reasons,” CFO and CBO Erich Horsley told Endpoints News. “The name Biosplice echoes our science much more than Samumed does.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.